Communications

Bis-heterocyclic systems based on 1,2,4-triazole-3-carboxamide as new anti-SARS-CoV2 agents

L. E. Grebenkina^a, A. V. Matveev^a, E. S. Oleynik^a, E. A. Pyankina^b, M. V. Chudinov^a, A. E. Siniavin^cd, V. A. Gushchin<sup>c

a</sup> M. V. Lomonosov Institute of Fine Chemical Technologies, MIREA – Russian Technological University, 119571 Moscow, Russian Federation
^b Surgut State University, 628412 Surgut, Russian Federation
^c N. F. Gamaleya National Research Center of Epidemiology and Microbiology, 123098 Moscow, Russian Federation
^d M. M. Shemyakin–Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russian Federation

Abstract: 5-Substituted analogs of the ribavirin heterocyclic base showed significant antiviral activity against SARS-CoV2 together with reduced toxicity, compared to ribavirin. Using the SARS-CoV2 attachment model, it was found that 5-(pyridin-4-yl)-1,2,4-triazole-3-carboxamide and 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxamide, as well as the isosteric derivative of the latter, namely, 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carbothioamide could act through inhibiting viral attachment to the cell.

Keywords: 1,2,4-triazole-3-carboxylates, ribavirin full deoxy analogs, antiviral agents, SARS-CoV2, acylamidrazones.

Received: 16.07.2025
Accepted: 17.10.2025

Language: English

DOI: 10.71267/mencom.7873